appears to play an early and potentially crucial role in the pathogenesis of progressive glomerular lesions and glomerular sclerosis, which may lead to irreversible loss of renal function. Indeed, in different experimental models of glomerular injury it has been observed that persistent MC proliferation is associated with expansion of the mesangial extracellular matrix (ECM) and glomerular sclerosis [1, 21. Moreover, experimental interventions inhibiting MC proliferation have been reported to limit mesangial ECM build-up and to lessen fall of renal function [3, 1. Numerous in vitro studies have identified substances which induce MC proliferation including, for instance, various peptide growth factors and nuclear transcription factors mediating the mitogenic response [5, 6] . The present study addressed the question, which cellular events are involved in anti-mitogenic effects on MCs. In particular, we studied molecular mechanisms of TGF-f31-related growth suppression in cultured MCs. It has been shown that TGF-f3 is produced by MCs in a constitutive fashion and can act upon MCs in an autocrine manner, including the induction of its own synthesis [7] . Of the three isoforms of TGF-J3 that have been identified in mammalian species, most data have been generated in studies of the 131 subtype, a 25 kDa homodimer. A recent histochemical study demonstrated elevated glomerular abundance of all three TGF-/3 isoforms in a variety of human glomerular diseases, suggesting that TGF-p plays a pathogenetically relevant role [8] . TGF-/3 isoforms are secreted proteins which undergo extracellular activation [9] . Much evidence has been provided showing that TGF-/31 can inhibit proliferation of various mesenchymal and non-mesenchymal cell types and that it also regulates the expression and deposition of ECM proteins and stimulates expression of integrin receptors [9, 10] . Multiple studies of MCs in culture have confirmed the anti-mitogenic [11, 121 and ECM-promoting [12, 13] potential of TGF-/31. Also, in experimental glomerular disease, TGF-f31 has been reported to exhibit both beneficial antimitogenic, anti-inflammatory effects [141 and harmful fibrogenic action [15-171. The anti-mitogenic action of TGF-131 in proliferative glomerular diseases is of particular interest. In cultured MCs, TGF-f31 has been observed to stimulate cell proliferation at low concentrations (< 100 pg/mI), while it strongly inhibited MC proliferation at higher concentrations (> 250 ng/ml) [11] . By using MCs as a vector for gene delivery to the renal glomerulus, a recent study in rats demonstrated that overexpression of active TGF-131 reduced MC hypercellularity in anti-Thyl.1 nephritis [14] .
It is presently unclear how the anti-mitogenic effects of TGF-/3 are mediated in MCs. Studies on various types of cultured cells, including tumor cell lines, have provided evidence that TGF-13 can induce cell cycle arrest by several mechanisms. Reports in epitheha! cells have linked the growth-inhibitory action of TGF-13 to its ability to block phosphorylation of the retinoblastoma gene product (pRb) [18] and of the pRb-related protein p130 [19] . Such effects of TGF-/3 appeared to be related to the induced expression or activity of nuclear inhibitors of cyclin-dependent kinases (cdks), such as pl5Th°4' [20, 211, p2i' [22] , or p27°1 [23] . In keratinocytes, TGF-/3 has been shown to directly interfere with transcription of c-myc by repressing its promotor activity through a TGF-j31 control element [24] . In the present study, we examined growth-inhibitory effects of TGF-pl in cultured rat MCs in order (1) to define more precisely the time phase during cell cycle progression when MCs are sensitive to TGF-/31-related inhibition, and (2) to identify regulatory steps of TGF-/31-induced cell cycle arrest in MCs.
Methods

Cell culture
Glomeruli from kidneys of male Sprague-Dawley rats (200 g) were isolated and glomerular outgrowth and subsequent subculturing of MCs was performed as described previously [251. MCs were kept in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated (5 0°C, 30 mm) fetal calf serum (FCS), 50 U/ml penicillin, 50 sg/ml streptomycin, 2 mrvi glutamin, and 5 ig/m1 insulin in a 95% air/5% CO2 humidified atmosphere at 37°C. MCs were used for experiments between passages 5 and 20. Before addition of specific growth regulators, MC quiescence was achieved by incubation for 72 hours in DMEM supplemented with 0.5% heat-inactivated FCS, 50 U/ml penicillin, 50 g/ml streptomycin, 2 mrvi glutamin, and 5 ig/ml insulin. Unless otherwise indicated, peptide growth factors were used in the following concentrations: PDGF-BB 25 ng/ml (Boehringer, Mannheim, Germany); TGF-/31 5 ng/ml (Life Technologies, Eggenstein, Germany); endothelin-1 10 flM (Boehringer); serotonin (5-HT) 1 m'vi (Sigma, Deisenhofen, Germany); bFGF 10 ng/ml (Boehringer); EGF 100 ng/ml (Boehringer).
Determination of 31-I-thymidine uptake A total of 1.5 x iO MCs/well were seeded using 96-well plates in medium supplemented with 10% FCS. After 24 hours, MCs were growth-arrested by culture in medium supplemented with 0.5% FCS for 72 hours. Quiescent MCs were then exposed to fresh medium containing 0.5% FCS with or without addition of various growth factors and pulsed with 1 sCi/ml [3H-methyl]-thymidine (specific activity 5 mCi/mmol; Amersham, Braunschweig, Germany). At indicated time points, MCs were washed twice with PBS, lysed with dH2O and harvested onto filter paper using an automated cell harvester (Bibby Dunn, Asbach, Germany). Incorporated counts were measured in a liquid scintillation counter (Beckman, Munchen, Germany). Triton X-100, 0.6 mvi PMSF, 100 U/mi Trasylol, 2 jtg/mI leupeptin, 100 IIM sodium orthovanadate). Protein concentration was determined using a commercially available assay based on the Bradford dye binding procedure (BioRad). Protein samples containing 20 tg total protein were denatured by boiling for five minutes and separated on a 10% denaturing SDS-PAGE gel. For detection of pRb, a 7.5% denaturing SDS-PAGE gel was used.
After electrophoresis, the gels were electroblotted onto NC membranes (BioRad) and the transfer was controlled by Ponceau-S staining. Blots were incubated in PBS containing 0.1% Tween-20 and 5% non-fat dry milk powder to block unspecific binding, washed in PBS containing 0.1% Tween-20 and incubated with primary antibodies. Applied primary antibodies were directed against: cyclin E, 1:500; cdk 2, 1:500; cyclin Dl, 1:500; cdk 4, 1:500; pRb, 1:500; all purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Applied secondary antibodies were peroxidase-conjugated goat anti-rabbit IgG, 1:10000 (Dianova). For visualization, the ECL system (Amersham) was used according to the manufacturer's protocol.
RNA extraction and Northern blot analysis
MCs were grown in 10 cm dishes until subconfluency and growth-arrested for 72 hours in medium containing 0.5% FCS. After stimulation with indicated stimuli for indicated times, cells were washed twice in PBS and total RNA was extracted by the method of Chomczynski and Sacchi [26] . Ethanol-precipitated * * I * .Ii!I.LI.
RNA was transferred onto Hybond nylon membrane (Amersham). Northern blots were baked at 80°C for two hours, prehybridized with 5 X Denhardts, 5 X SSC, 50% formamide, 50 m Na3PO4, 0.1% SDS, 0.25 mg/mI salmon sperm DNA at 65°C for four hours. The DNA hybridization probes were labeled with [a-32P]dCTP using a random primer labeling kit (Boehringer).
Blots were hybridized in prehybridization solution containing 2 >< 106 cpm/ml of probe at 55°C for 16 hours. Next, blots were washed twice for 15 minutes with 2 X SSC containing 0.1% SDS and then 30 minutes with 0.1 >< SSC containing 0.1% SDS. Blots were exposed to Kodak XAR-2 films with intensifying screens at -80°C.
Cyclin E-associated histone Hi kinase activity Seven hours after mitogenic stimulation whole-cell protein extracts of MCs were prepared by lysis in hepes-buffer (50 mivi Hepes, pH 7.0, 150 mM NaC1, 0.1% NP-40, 0.2 mvt PMSF, 100 fLM sodium orthovanadate, 10 mivi 3-glycerophosphate, 1 mrvi NaF, 0,33 TIU/ml aprotinin). After preclearing with 40 pi protein A-agarose, protein extracts (500 .tg) were immunoprecipitated for one hour at 4°C with an antibody specific for cyclin E (Santa Cruz Biotechnology), which during G1 phase is associated with active cdk 2. Cyclin E-associated kinase activity in the immunoprecipitates was determined using histone Hi as substrate [27] . Immune complexes were resuspended in 35 d kinase buffer containing 0.26 mg/mI histone Hi (Sigma), 1 jtM cold ATP, 0.5 mCi/ml were terminated by heating at 95°C for 10 minutes. Phosphorylated products were analyzed on a 10% SDS-polyacrylamide gel and visualized by autoradiography. Exposure time was about one hour. After scanning densitometry, results were correlated with cdk 2 protein abundance in each immunoprecipitate, assessed by Western blot analysis. By Western blot, cdc 2 protein was not detectable in cyclin E immune complexes from MCs lysed seven hours after mitogenic stimulation.
Statistical analysis
Statistical analysis was performed using Student's t-test for unpaired samples.
Results
TGF-/31 inhibits mitogen-induced proliferation of MCs
Initial studies were performed to obtain information on mitogenic and anti-mitogenic effects and dose-responses of TGF-f31 and other MC growth regulators. TGF-131 (5 ng/ml) significantly inhibited mitogenesis induced by PDGF (25 ng/ml), EGF (100 ng/ml), serotonin (1 mM), endothelin-i (10 nM), or bFGF (10 ng/ml), as assessed by 3H-thymidine uptake (Fig. 1) , These results indicated that the growth-inhibitory effects of TGF-f31 involve mechanisms independent from the type and trans-receptor signaling modes of different mitogens. To study anti-mitogenic signaling mechanisms of TGF-/3i, we focused on the antagonistic growthregulatory effects of PDGF and TGF-f31. was applied at 25 ng/ml concentrations which induced a 3.4-fold increase in MC DNA replication. Incubation of MCs with increasing concentrations of TGF-131 induced a biphasic dose response (Fig. 2B) . A maximum 2.1-fold increase of DNA synthesis was caused by 0.05 ng/ml TGF-131. However, higher (> 0.5 ng/ml) or lower (< 0.005 ng/ml) concentrations of TGF-pl did not increase 3H-thymidine uptake. TGF-j31 concentrations > 0.5 ng/ml further decreased DNA synthesis of quiescent MCs.
TGF-/3i did not only prevent PDGF-induced DNA synthesis ( Fig. 1 ), but also significantly decreased MC proliferation elicited by PDGF (Fig. 3) . Counts of MCs incubated with PDGF (25 ng/ml) and/or TGF-f3i (5 ng/mI) were determined on days 2, 3 and 4 after stimulation (Fig. 3) . While PDGF led to a 1.7-fold increase of MC counts on day 4, incubation of MCs with TGF-/31 alone had no effect. Simultaneous incubation of MCs with PDGF and TGF-pl significantly inhibited the proliferative response of MCs, roughly correlating with the results of DNA synthesis ( Figs. 1 and  3 ). Since the number of TGF-f31 -treated cells did not fall below the 0.5% FCS control value, toxicity of TGF-f31 at a concentration of 5 ng/ml did not seem to be involved in its observed antimitogenic effect.
Inhibition of PDGF-induced mitogenesis by TGF-131 is dependent on time of addition
The results shown in Figure 4 indicate that TGF-pl did not interfere with very early mitogenic signaling effects induced by PDGF. Growth-arrested MCs were incubated with PDGF (25 ng/ml). TGF-/31 (5 ng/ml) was then added to PDGF-stimulated MCs at time-points 0 to 18 hours. TGF-f31 significantly inhibited PDGF-induced DNA synthesis when added within the first six hours. The addition of TGF-pl at eight or more hours after PDGF stimulation was no longer able to suppress MC growth promotion initiated by PDGF. This finding led to the following experiments addressing the question, which mitogenic signaling events are target of TGF-pl. (Fig. 5) . Quiescent MCs were stimulated with PDGF (25 ng/ml) or PDGF (25 nglml) plus TGF-pl (5 nglml). MCs were harvested at various time points ranging from 0 to 34 hours and percentages of cells in G0/G1, 5, or G2/M phases of cell cycle were determined. By serum deprivation, an average of 82% of MCs were arrested in G01G1 phase, 6% in S phase and 12% in G2/M phase. After PDGF stimulation, the percentage of cells in G0/G1 phase decreased to 50% at 20 hours. A maximum of 28% ofMCs could be detected in S phase at 16 hours (Fig. 5A) . Entry into S phase occurred 14 hours after PDGF stimulation and exit from S phase was detected between 20 and 24 hours. Coincubation with TGF-pl, however, almost completely prevented PDGF-driven transition of MCs from G01G1 phase into S phase (Fig. SB) . Failure to enter S, G2 and M phases in the TGF-J31 -treated MCs could be due to arrest in G phase or failure to enter G1 phase. To address this question, the effects of TGF-131 on markers of PDGF-induced cell cycle entry were examined for which we used expression of (1) immediate early genes and of (2) G phase cyclins and cyclin-dependent kinases.
TGF-pl does not affect PDGF-induced immediate early gene (lEG) expression in MCs
Upon incubation with PDGF, Northern blot analysis demonstrated a rapid and transient increase of mRNA abundance of the lEGs, c-fos, Egr-1, and c-jun (Fig. 6) . TGF-/31 did not change mRNA expression of either one of these PDGF-induced lEGs. Thus, interference with mitogen-related lEG expression did not appear to be a target of anti-mitogenic signaling initiated by TGF-pl.
Protein expression of the G1 phase cyclins and cyclin-dependent kinases
The protein abundance of the G1 phase cyclins Dl, E and cyclin-dependent kinases (cdks) 2 and 4 was determined by Western blot (Fig. 7) . Quiescent MCs were stimulated with PDGF (25 ng!ml) or PDGF (25 nglml) plus TGF-131 (5 ng/ml). Cyclin E was expressed at rather high abundance in quiescent MCs and its expression level was only marginally enhanced after stimulation with PDGF. However, incubation with PDGF caused an increase in protein expression of cyclin Dl, cdk 2 and cdk 4 between 8 and 10 hours. Coincubation with TGF-131 did not influence the protein abundance of either one of these proteins: the expression level of cyclin E was not suppressed below baseline and the PDGFinduced expression of cyclin Dl, cdk 2 or cdk 4 was not measurably altered by TGF-pl. The finding that TGF-f31 did not influence PDGF-induced expression of the lEGs, c-fos, Egr-1, c-jun and of cyclin Dl, cdk 2 or cdk 4 indicated that anti-mitogenic actions of TGF-f31 occur after MCs have entered G1 phase and before progressing to S phase. Next, we examined how TGF-/31 interferes with molecular mechanisms involved in orderly progression through G1 phase.
TGF-/31 inhibits phosphoiylation of retinoblastoma protein
We examined whether regulation of retinoblastoma protein (pRb) phosphorylation contributed to TGF-/31-induced G1 phase arrest. In its hypophosphorylated state, pRb is active, inhibiting progression from G1 into S phase [18] . On Western blots, the proportions of hypo-or hyperphosphorylated pRb are apparent by mobility shift. While the hypophosphorylated (active) protein species is detected at 105 kDa, the hyperphosphorylated (inactive) protein species migrates more slowly on gel electrophoresis and can be detected between 110 and 116 kDa [28, 29] . As shown in TGF-131 inhibits mitogen-induced cyclin E-associated histone HI kinase activity in rat MCs We examined the effect of TGF-pi on mitogen-induced cyclin F-associated histone Hi kinase activity. Active cyclin E-cdk 2 complexes contribute to phosphorylate pRb and are required for progression of cells from G1 into S phase. As depicted in Figure  9 , both, 10% FCS and PDGF strongly induced cyclin E-associated histone Hi kinase activity in quiescent MCs at seven hours after stimulation compared to 0.5% FCS controls. Coincubation of PDGF-stimulated MCs with TGF-131 clearly inhibited cyclin E-associated histone Hi kinase activity compared to MCs treated with PDGF alone. Incubation of unstimulated control cells with TGF-/31 had no effect on cyclin E-associated histone Hi kinase activity. Because cyclin E does not have any known partner during G1 other than cdk 2, the kinase activity that is down-regulated by TGF-13i during G1 corresponds largely, if not exclusively, to the activated cyclin E-cdk 2 complex. The cyclin E-associated cdk 2 protein amounts were assessed by Western blot analysis and were not significantly altered by TGF-/31, indicating that TGF-J31 did not interfere with the assembly of cyclin E-cdk 2 complexes in rat MCs (data not shown). Calculated ratios of the densitometric values of bands of histone Hi phosphorylation (Fig. 9B) over cdk 2 protein expression by Western blot revealed an 3.4-fold increase for 10% FCS and an 3.3-fold increase for PDGF over 0.5% FCS controls. Addition of TGF-f3 together with PDGF reduced this effect to a value of 1.1-fold over controls.
Discussion
In inflammatory glomerular disease, glomerular hypercellularity due to MC proliferation has been associated with the development of glomeruloscierosis and progressive loss of renal function. The concept has been advanced that ongoing MC replication also activates the synthetic-secretory phenotype of MCs which After one, two, four, and six hours, total RNA was extracted and subjected to Northern blot analysis using c-fos, Egr-1, and c-jun eDNA probes. Equal RNA loads were confirmed by hybridization with a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) eDNA probe.
contributes to mesangial ECM expansion and may ultimately lead to glomerular scarring [2-41. In several animal models, stimulation of MC proliferation was found to be related to increased deposition of ECM [1, 2] and interventions inhibiting proliferation lessened matrix expansion [3, 4] . In contrast to the large amount of information available on mitogenic mechanisms involved in the pathogenesis of glomerular immune injury, little is known about counterbalancing antiproliferative actions which allow resolution of hypercellular glomerulonephritis (GN). Recent reports have suggested protective, anti-inflammatory and/or anti-mitogenic effects in the inflamed glomerulus for various regulators and mechanisms, including (1) the anti-inflammatory lymphokines IL-4 and IL-b that are secreted by T helper subset 2 lymphocytes [301, (2) apoptotic cell clearing mechanisms contributing to reduction of MC hypercellularity [31, 32] , and (3) TGF-13 by virtue of its anti-inflammatory and anti-mitogenic actions [14] . While a recent study has demonstrated that glomerular overexpression of active TGF-1 significantly reduced gbmerular mitogenesis in anti-Thy 1.1 nephritis [14] , TGF-13 has also been implied to promote accumulation of ECM in glomerular disease [15] [16] [17] . The diverse effects of TGF-j3 have been found to be mediated by different receptor-mediated signaling pathways, with the type I TGF-13 receptors being responsible for effects on ECM production, and the type II TGF-f3 receptors mediating growth inhibition [33] . Little information exists on post-receptor signaling pathways leading to anti-mitogenic actions of TGF-/3 in MCs. Recently, TGF-J3 has been suggested to be an endogenous activator of the growth inhibitory pathway mediated by protein kinase C [34] . In the present study, we investigated nuclear mechanisms involved in anti-mitogenic signaling by TGF-13 in MCs.
Our results confirm that TGF-j31 modulates MC growth in a biphasic manner with low concentrations inducing [11] and higher concentrations inhibiting MC proliferation [11, 12] . The mechanism of how TGF-131 increases MC proliferation at low concentrations around 0.05 ng/ml is presently unclear and remains the subject of further investigation. At 5 ng/ml concentrations, TGF-131 markedly inhibited proliferation of MCs stimulated with various mitogens, including PDGF, EGF, serotonin, endothelin-1, and bFGF. These results indicate that the growth-inhibitory potential of TGF-f31 acts in a manner that is independent of the type of mitogen receptor-mediated signaling pathway. Results generated in other cell types have linked TGF-J3-induced antimitogenic actions to 1 phase arrest [35] . We found that the potential of TGF-131 to inhibit PDGF-induced mitogenesis was dependent on the time of addition of TGF-31. It was limited to a time period of up to eight hours after mitogenic stimulation. observe a marked PDGF-induced increase of cyclin E protein expression. This could be explained by the high constitutive abundance of cyclin E even in quiescent cultured MCs.
To address the question of how TGF-pl interferes with molecular mechanisms involved in the progression through the G1 phase, we examined the phosphorylation of the negative cell cycle regulator protein, pRb, in MCs. In its hypophosphorylated state, the tumor supppressor pRb is active, thus inhibiting progression from G1 phase into S-phase [18] . During progression of cells from G1 phase into S phase, pRb is phosphorylated by active cyclin D-cdk 4/6 and cyclin E-cdk 2 complexes [18] . We observed that the PDGF-induced pRb phosphorylation in MCs was inhibited by Several molecular mechanisms have been proposed to explain the ability of TGF-131 to prevent pRb phosphorylation. While inhibition of pRb phosphorylation by TGF-f3 appears to be a major cause of TGF--induced growth arrest in a variety of cell types, there may be cell-specific preferences as to the molecular mechanisms involved. For example, TGF-/31 reduced cdk 4 protein abundance in responsive epithelial cell lines [37] . In mitogenstimulated MCs, we did not observe a significant influence of TGF-f31 on cdk 4 protein expression. Mink lung epithelial cells treated with TGF-f3 failed to stably assemble cyclin E-cdk 2 complexes, which in turn caused decreased cdk 2 activity [27] . These effects of TGF-p were correlated with inhibition of pRb phosphorylation [27] . In MCs, the cyclin F-associated cdk 2 protein amounts were not significantly altered by TGF-f31, indicating that TGF-/31 did not interfere with the assembly of cyclin E-cdk 2 complexes. However, we demonstrate that TGF-31 significantly inhibits PDGF-induced cyclin E-associated kinase activity. Cyclin E does not have any known partner during G1 phase other than cdk 2. Therefore, the kinase activity that is down-regulated by TGF-pl during G1 phase corresponds largely, if not exclusively, to the activated cyclin E-cdk 2 complex. The inhibition of cyclin E-cdk 2 kinase activity by TGF-pi may represent an important mechanism leading to G1-arrest in MCs.
Recently, several nuclear inhibitors of cyclin-dependent kinases have been identified in non-glomerular cell types. Their expression or activity can be induced by TGF-J3. These cdk inhibitors include p15'"41' [20, 21] , p21C' [22] and p27" [23] . While p15INK4b is an inhibitor of cdks 4 or 6, p2lC' and p27" were shown to inhibit cdk 2 activities, as well. In preliminary experiments, we have very recently observed that TGF-j31 increases mRNA expression of p1 in resting rat MCs (Schoecklmann and Sterzel, unpublished results). It is presently unclear whether the anti-mitogenic effects of TGF-f31 on MCs involve the induction of this or other cdk inhibitors, such as p2l or p27. Recent findings by Terada et al [38] and Shankland et al [39] have shown that some of these nuclear proteins may well be relevant for the regulation of cell cycle progression and proliferation of MCs in culture and in vivo. Further studies are required to fully understand the precise function of TGF-f3 and these regulators during glomerular inflammation as well as their potential for diagnostic and therapeutic approaches in mesangioproliferative diseases of the kidney. 
